Prenetics posts 480% revenue surge to $92.4M as IM8 hits $120M ARR
Prenetics’ full-year 2025 revenue rose 480% to $92.4 million, with Q4 sales reaching $36.6 million, driven by IM8’s breakout performance. The company achieved $120 million in ARR within 12 months, finalized strategic divestitures, and bolstered adjusted liquidity to $171 million with zero debt.
1. Record Financial Results
The company delivered full-year 2025 revenue of $92.4 million, up 480% year-over-year, and Q4 revenue of $36.6 million, a 55% quarter-over-quarter increase.
2. IM8 Breakout Performance
IM8 generated $60.1 million in FY2025 revenue, achieved $10 million in monthly revenue by December, and reached $120 million in ARR within its first 12 months, reflecting exceptional product-market fit and subscription growth.
3. Strategic Divestitures and Balance Sheet
Prenetics completed the sale of ACT Genomics for up to $72 million, Europa distribution for $13 million in stock, and its Insighta stake for $70 million, resulting in $171 million in adjusted liquidity and zero debt as of mid-February 2026.
4. Global Expansion and Unit Economics
IM8 shipped to over 30 countries, with 61% of revenue generated outside the US and top-five markets accounting for $45.9 million; unit economics show a 3.5-month payback period, 60% gross margins, and a projected LTV:CAC above 3x after quarterly subscription rollout.